The MDL now includes thousands of cases, and in an August 15, 2025 memorandum, Judge Marston set strict diagnostic requirements for gastroparesis claims, instructing plaintiffs to prove the condition with objective gastric emptying tests rather than symptoms alone
Metabolic indicators that may correlate with reduced GLP-1 activity include: Persistent hyperglycemia despite dietary modifications, particularly elevated postprandial (after-meal) blood glucose levels Difficulty achieving satiety after meals, leading to continued hunger and frequent snacking Progressive weight gain that is resistant to conventional dietary interventions Diagnosis of prediabetes or type 2 diabetes , conditions associated with impaired incretin response Metabolic syndrome features , including central obesity, hypertension, and dyslipidemia It is important to emphasize that these signs are not diagnostic of GLP-1 imbalance specifically, as they can result from numerous metabolic, endocrine, or lifestyle factors
Protein-rich meals produce a stronger GLP-1 response than carbohydrate-heavy meals of the same calorie count
It is not recommended to use Semaglutide during pregnancy or while breastfeeding, as its effects on fetal development and lactation are not fully understood
Using the peptides together allows researchers to explore how intracellular structural dynamics, vascular signaling pathways, and extracellular matrix interactions converge in complex tissue environments
